The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2025 | Evaluating the role of pan-RAF inhibitors in BRAF-mutant NSCLC
Tadashi Manabe, MD, PhD, University of California, San Francisco, CA, suggests that exarafenib could be a first-choice treatment for patients with BRAF Class II and III alterations, as well as those with Class I alterations who have developed resistance to first-generation RAF inhibitors. The efficacy of exarafenib against dimerized BRAF oncoproteins, which are often resistant to first-generation RAF inhibitors, presents an opportunity to treat patients who have developed resistance to these earlier therapies. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
